Open Access
Issue
Med Sci (Paris)
Volume 35, Number 6-7, Juin-Juillet 2019
Page(s) 497 - 500
Section Le Magazine
DOI https://doi.org/10.1051/medsci/2019105
Published online 05 July 2019
  1. Maude SL, Laetsch TW, Buechner J, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med 2018 ; 378 : 439–448. [CrossRef] [Google Scholar]
  2. Mitchell K, Barreyro L, Todorova TI, et al. IL1RAP potentiates multiple oncogenic signaling pathways in AML. J Exp Med 2018 ; 215 : 1709–1727. [CrossRef] [PubMed] [Google Scholar]
  3. Jaras M, Johnels P, Hansen N, et al. Isolation and killing of candidate chronic myeloid leukemia stem cells by antibody targeting of IL-1 receptor accessory protein. Proc Natl Acad Sci USA 2010 ; 107 : 16280–16285. [CrossRef] [Google Scholar]
  4. Zhao K, Yin LL, Zhao DM, et al. IL1RAP as a surface marker for leukemia stem cells is related to clinical phase of chronic myeloid leukemia patients. Int J Clin Exp Med 2014 ; 7 : 4787–4798. [Google Scholar]
  5. Warda W, Larosa F, Neto Da Rocha M, et al. CML Hematopoietic stem cells expressing IL1RAP can be targeted by chimeric antigen receptor-engineered T cells. Cancer Res 2019 ; 79 : 663–675. [CrossRef] [Google Scholar]
  6. Blatt K, Menzl I, Eisenwort G, et al. Phenotyping and target expression profiling of CD34+/CD38- and CD34+/CD38+ stem and progenitor cells in acute lymphoblastic leukemia. Neoplasia 2018 ; 20 : 632–642. [CrossRef] [Google Scholar]
  7. Barreyro L, Will B, Bartholdy B, et al. Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS. Blood 2012 ; 120 : 1290–1298. [CrossRef] [Google Scholar]
  8. Zheng P, Zhang Y, Zhang B, et al. Synthetic human monoclonal antibody targets hIL1 receptor accessory protein chain with therapeutic potential in triple-negative breast cancer. Biomed Pharmacother 2018 ; 107 : 1064–1073. [CrossRef] [PubMed] [Google Scholar]
  9. Agerstam H, Hansen N, von Palffy S, et al. IL1RAP antibodies block IL-1-induced expansion of candidate CML stem cells and mediate cell killing in xenograft models. Blood 2016 ; 128 : 2683–2693. [CrossRef] [Google Scholar]
  10. Agerstam H, Karlsson C, Hansen N, et al. Antibodies targeting human IL1RAP (IL1R3) show therapeutic effects in xenograft models of acute myeloid leukemia. Proc Natl Acad Sci USA 2015 ; 112 : 10786–10791. [CrossRef] [Google Scholar]
  11. Ruella M, Xu J, Barrett DM, et al. Induction of resistance to chimeric antigen receptor T cell therapy by transduction of a single leukemic B cell. Nat Med 2018 ; 24 : 1499–1503. [CrossRef] [PubMed] [Google Scholar]
  12. Catros V.. Les CAR-T cells, des cellules tueuses spécifiques d’antigènes tumoraux : de nouvelles générations pour le traitement des tumeurs solides. Med Sci (Paris) 2019 ; 35 : 316–326. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]
  13. Jordan B.. Immunothérapie CAR-T : une autorisation qui fait date. Med Sci (Paris) 2017 ; 33 : 1003–1006. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.